Sage Therapeutics Company Profile (NASDAQ:SAGE)

About Sage Therapeutics

Sage Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. Its product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. Its SAGE-718 is a product candidate selected for development from its NMDA receptor program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SAGE
  • CUSIP:
Key Metrics:
  • Previous Close: $38.57
  • 50 Day Moving Average: $40.32
  • 200 Day Moving Average: $34.77
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.95
  • P/E Growth: 0.00
  • Market Cap: $1.24B
  • Outstanding Shares: 32,094,000
  • Beta: 2.77
Additional Links:
Companies Related to Sage Therapeutics:

Analyst Ratings

Consensus Ratings for Sage Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 1 Sell Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $70.10 (81.75% upside)

Analysts' Ratings History for Sage Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetDetails
8/12/2016BMO Capital MarketsReiterated RatingBuy$57.00View Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00View Rating Details
7/12/2016JPMorgan Chase & Co.Reiterated RatingBuy$71.00View Rating Details
7/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details
7/12/2016Chardan CapitalReiterated RatingSellView Rating Details
7/12/2016Leerink SwannReiterated RatingBuy$66.00View Rating Details
6/23/2016HC WainwrightInitiated CoverageBuy$56.00View Rating Details
6/8/2016Canaccord GenuityReiterated RatingBuyView Rating Details
4/1/2016Goldman Sachs Group Inc.Reiterated RatingBuy$63.00View Rating Details
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00View Rating Details
1/27/2015SunTrust Banks Inc.Initiated CoverageBuy$67.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Sage Therapeutics (NASDAQ:SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sage Therapeutics (NASDAQ:SAGE)
Current Year EPS Consensus Estimate: $-4.42 EPS
Next Year EPS Consensus Estimate: $-4.85 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.99)($0.91)($0.95)
Q2 20164($1.12)($0.94)($1.03)
Q3 20165($1.22)($1.07)($1.13)
Q4 20165($1.29)($1.12)($1.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sage Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sage Therapeutics (NASDAQ:SAGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sage Therapeutics (NASDAQ:SAGE)
DateHeadline
News IconWall Street Ratings and Update on Sage Therapeutics, Inc. (NASDAQ:SAGE) - Post News (NASDAQ:SAGE)
www.kentuckypostnews.com - August 25 at 12:20 PM
News IconCrowd & Street Views on Sage Therapeutics, Inc. (NASDAQ:SAGE ... - Post News (NASDAQ:SAGE)
www.kentuckypostnews.com - August 18 at 7:30 PM
finance.yahoo.com logoSAGE THERAPEUTICS, INC. Financials (NASDAQ:SAGE)
finance.yahoo.com - August 17 at 7:38 PM
News IconSage Therapeutics Inc. (NASDAQ: SAGE) Buy rating reiterated at ... - BNB Daily (blog) (NASDAQ:SAGE)
www.baseball-news-blog.com - August 15 at 9:26 AM
finance.yahoo.com logoSage Therapeutics Announces Second Quarter 2016 Financial ... - Yahoo Finance (NASDAQ:SAGE)
finance.yahoo.com - August 11 at 7:48 PM
businesswire.com logoSage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update - Business Wire (press release) (NASDAQ:SAGE)
www.businesswire.com - August 11 at 7:48 PM
finance.yahoo.com logoSage Therapeutics reports 2Q loss - Yahoo Finance - Yahoo Finance (NASDAQ:SAGE)
finance.yahoo.com - August 11 at 7:48 PM
bizjournals.com logoHow These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma (NASDAQ:SAGE)
www.bizjournals.com - August 10 at 7:45 PM
News IconSage Therapeutics (SAGE) Tumbles on Q2 Loss (NASDAQ:SAGE)
www.economiccalendar.com - August 10 at 7:45 PM
reuters.com logoBRIEF-Sage Therapeutics Q2 EPS ($1.08) - Reuters (NASDAQ:SAGE)
www.reuters.com - August 10 at 10:24 AM
twst.com logoSage Therapeutics Inc.: Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides ... - The Wall Street Transcript (NASDAQ:SAGE)
www.twst.com - August 10 at 10:24 AM
News IconUnder Armour Inc (NYSE:UA) & SAGE Therapeutics (NASDAQ:SAGE) Trader's Round Up - Money News (press release) (NASDAQ:SAGE)
www.newsismoney.com - August 10 at 10:24 AM
News Iconanalysts Recommendations: Sage Therapeutics, Inc. (NASDAQ ... - News Oracle (NASDAQ:SAGE)
www.newsoracle.com - August 10 at 10:24 AM
thestreet.com logoSAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss (NASDAQ:SAGE)
www.thestreet.com - August 9 at 7:33 PM
sg.finance.yahoo.com logoSage Therapeutics reports 2Q loss (NASDAQ:SAGE)
sg.finance.yahoo.com - August 9 at 10:29 AM
finance.yahoo.com logo6:50 am SAGE Therapeutics reports Q2 EPS of ($1.08) vs ($1.02) Capital IQ Consensus Estimate; co did not report any revs (NASDAQ:SAGE)
finance.yahoo.com - August 9 at 10:29 AM
publicnow.com logoSage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:SAGE)
www.publicnow.com - August 9 at 10:29 AM
finance.yahoo.com logoSage Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:SAGE)
finance.yahoo.com - August 3 at 7:38 PM
publicnow.com logoSage Therapeutics to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016 (NASDAQ:SAGE)
www.publicnow.com - August 2 at 7:37 PM
finance.yahoo.com logoHow To Get A 1-On-1 With An Expert On SAGE-547 (NASDAQ:SAGE)
finance.yahoo.com - July 28 at 5:24 PM
finance.yahoo.com logoImportance Of Phase 2 Trials (NASDAQ:SAGE)
finance.yahoo.com - July 25 at 9:14 AM
streetinsider.com logoForm 8-K Sage Therapeutics, Inc. For: Jul 15 - StreetInsider.com (NASDAQ:SAGE)
www.streetinsider.com - July 22 at 7:02 PM
News IconSage Therapeutics Incorporated (NASDAQ:SAGE) Sellers Increased By 20.32% Their Shorts - Consumer Eagle (NASDAQ:SAGE)
www.consumereagle.com - July 22 at 7:02 PM
News IconWhat's Next for SAGE Therapeutics Inc After Today's Huge Increase? - Consumer Eagle (NASDAQ:SAGE)
www.consumereagle.com - July 22 at 7:02 PM
finance.yahoo.com logoEdited Transcript of SAGE earnings conference call or presentation 5-May-16 8:30pm GMT (NASDAQ:SAGE)
finance.yahoo.com - July 22 at 3:18 PM
biz.yahoo.com logoSAGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem (NASDAQ:SAGE)
biz.yahoo.com - July 21 at 4:11 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Sage Therapeutics, Inc. (NASDAQ:SAGE) - TGP (NASDAQ:SAGE)
telanaganapress.com - July 21 at 10:04 AM
News IconSage Therapeutics, Inc. (NASDAQ:SAGE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:SAGE)
www.engelwooddaily.com - July 20 at 8:06 PM
News IconSolid Performer in Focus: Sage Therapeutics, Inc. (NASDAQ:SAGE) - Engelwood Daily (NASDAQ:SAGE)
www.engelwooddaily.com - July 20 at 8:06 PM
finance.yahoo.com logoSage Appoints Geno Germano to Company's Board of Directors (NASDAQ:SAGE)
finance.yahoo.com - July 19 at 7:00 AM
News IconTrading Performance and Target Watch for Sage Therapeutics, Inc. (NASDAQ:SAGE) - Press Telegraph (NASDAQ:SAGE)
presstelegraph.com - July 18 at 12:50 PM
News IconStock in Positive Territory for the Quarter: Sage Therapeutics, Inc. (NASDAQ:SAGE) - Engelwood Daily (NASDAQ:SAGE)
www.engelwooddaily.com - July 18 at 12:50 PM
tradecalls.org logoShares of Sage Therapeutics (SAGE) Rally 24.29% - Trade Calls (NASDAQ:SAGE)
www.tradecalls.org - July 18 at 12:50 PM
marketexclusive.com logoDid SAGE Therapeutics Inc (NASDAQ:SAGE) Just Cure Depression? (NASDAQ:SAGE)
marketexclusive.com - July 13 at 7:40 PM
biz.yahoo.com logoSAGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:SAGE)
biz.yahoo.com - July 13 at 4:58 PM
News IconRatings Analysis of: Sage Therapeutics, Inc. (NASDAQ:SAGE) - News Oracle (NASDAQ:SAGE)
www.newsoracle.com - July 13 at 10:07 AM
smarteranalyst.com logoJP Morgan Reiterates Overweight on SAGE Therapeutics Inc (SAGE) Following Positive Top-Line Phase 2 Data - Smarter Analyst (NASDAQ:SAGE)
www.smarteranalyst.com - July 13 at 10:07 AM
schaeffersresearch.com logoBuzz Stocks: Alcoa Inc, Fastenal Company, and SAGE Therapeutics Inc - Schaeffers Research (blog) (NASDAQ:SAGE)
www.schaeffersresearch.com - July 13 at 10:07 AM
news.cmlviz.com logoSage Therapeutics Inc Realized Volatility Hits Extreme Level - CML News (NASDAQ:SAGE)
news.cmlviz.com - July 13 at 10:07 AM
News IconCoverage of Top Gainers SAGE Therapeutics, Seagate Technology, and Cascadian Therapeutics (NASDAQ:SAGE)
news.investornetwork.com - July 13 at 9:26 AM
finance.yahoo.com logoHere's Why Sage Therapeutics (SAGE) Stock is Soaring 40% Today (NASDAQ:SAGE)
finance.yahoo.com - July 12 at 7:29 PM
cnbc.com logoAfter-hours buzz: JUNO, TEVA, SAGE & more (NASDAQ:SAGE)
www.cnbc.com - July 12 at 6:14 PM
cnbc.com logoSage Therapeutics shares soar on positive postpartum depression drug results (NASDAQ:SAGE)
www.cnbc.com - July 12 at 5:19 PM
thestreet.com logoSage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results (NASDAQ:SAGE)
www.thestreet.com - July 12 at 4:31 PM
benzinga.com logoSage's Phase 2 Clinical Trial Of SAGE-547 Achieves Primary Endpoint In Severe Postpartum Depression (NASDAQ:SAGE)
www.benzinga.com - July 12 at 11:39 AM
finance.yahoo.com logoSage Surges After Postpartum Drug Meets Goals in Trial (NASDAQ:SAGE)
finance.yahoo.com - July 12 at 11:39 AM
News IconSage's drug for postpartum depression succeeds in mid-stage study (NASDAQ:SAGE)
www.channelnewsasia.com - July 12 at 11:39 AM
News IconSage Therapeutics (SAGE) Boosted by Promising Postpartum Depression Drug Data (NASDAQ:SAGE)
www.economiccalendar.com - July 12 at 11:39 AM
schaeffersresearch.com logoBuzz Stocks: Alcoa Inc, Fastenal Company, and SAGE Therapeutics Inc (NASDAQ:SAGE)
www.schaeffersresearch.com - July 12 at 11:39 AM
wsj.com logoStocks to Watch: Starbucks, Sage Therapeutics, Seagate Technology (NASDAQ:SAGE)
blogs.wsj.com - July 12 at 11:39 AM

Social

Sage Therapeutics (NASDAQ:SAGE) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff